Value
1.8/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.1 |
| Analyst target | 3.0 |
- ▸Expensive valuation
NTRA · Why this verdict
Why Natera (NTRA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Natera is the industry growth leader in diagnostics with 39% revenue growth year-over-year, FCF-positive despite GAAP losses, and a Rule of 40 score of 44, but faces three consecutive earnings misses and a low asymmetry ratio at current price levels, making the thesis dependent on growth rate sustainability.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Natera has achieved FCF-positive status despite GAAP losses, with a free cash flow margin of 5% and FCF yield of 0.4%, signaling the business has crossed an important inflection point where growth spending is generating sustainable cash returns. Quality breakdown | FCF margin improves above 8% over the next 12 months as operating leverage from the 39% revenue growth rate flows through to cash generation. | →Stable |
| CounterFCF margin of only 5% is thin and a quality score of 4.7 remains below the high-quality threshold; a single quarter of working capital headwinds could reverse the FCF-positive status. | ||
Natera is ranked as the industry growth leader in diagnostics and research with revenue growing 39% year-over-year, a perfect growth score of 10.0, and a Rule of 40 score of 44, reflecting a rare combination of high growth and improving profitability. Growth breakdown | Revenue growth rate remains above 25% year-over-year and the Rule of 40 score stays above 35 over the next 12 months. | →Stable |
| CounterExtremely high growth rates at scale become increasingly difficult to maintain; reimbursement dynamics in genetic testing can change rapidly if payer policy shifts reduce coverage. | ||
Natera has missed analyst EPS estimates in 3 of the last 4 quarters, with the most recent miss of -8.5% indicating that the company's cost structure is growing faster than analysts model even as revenues outperform. Bear case | Natera returns to beating earnings estimates in at least 2 of the next 4 quarters as operating leverage reduces the gap between revenue growth and cost growth. | →Stable |
| CounterThe one quarter of beating (February 2026, +167.5% EPS surprise) shows the business can dramatically beat when conditions align; the large variance suggests analyst models lack visibility rather than fundamental deterioration. | ||
Natera has received positive news sentiment at a score of +0.67 and is exhibiting a breakout chart pattern with golden cross, above all moving averages, and RSI at 60, suggesting institutional accumulation is supporting the bullish fundamental thesis. Bull case | Price reaches the analyst consensus target of $234.05 within 12 months, representing approximately 7.9% upside from current levels. | →Stable |
| CounterThe asymmetry ratio of only 0.6 means downside risk of 13.1% outweighs the 7.9% upside, and three consecutive earnings misses suggest the market has already discounted some of the good news. | ||
Natera has achieved FCF-positive status despite GAAP losses, with a free cash flow margin of 5% and FCF yield of 0.4%, signaling the business has crossed an important inflection point where growth spending is generating sustainable cash returns.
→StableQuality breakdown
- Expectation
- FCF margin improves above 8% over the next 12 months as operating leverage from the 39% revenue growth rate flows through to cash generation.
CounterFCF margin of only 5% is thin and a quality score of 4.7 remains below the high-quality threshold; a single quarter of working capital headwinds could reverse the FCF-positive status.
Natera is ranked as the industry growth leader in diagnostics and research with revenue growing 39% year-over-year, a perfect growth score of 10.0, and a Rule of 40 score of 44, reflecting a rare combination of high growth and improving profitability.
→StableGrowth breakdown
- Expectation
- Revenue growth rate remains above 25% year-over-year and the Rule of 40 score stays above 35 over the next 12 months.
CounterExtremely high growth rates at scale become increasingly difficult to maintain; reimbursement dynamics in genetic testing can change rapidly if payer policy shifts reduce coverage.
Natera has missed analyst EPS estimates in 3 of the last 4 quarters, with the most recent miss of -8.5% indicating that the company's cost structure is growing faster than analysts model even as revenues outperform.
→StableBear case
- Expectation
- Natera returns to beating earnings estimates in at least 2 of the next 4 quarters as operating leverage reduces the gap between revenue growth and cost growth.
CounterThe one quarter of beating (February 2026, +167.5% EPS surprise) shows the business can dramatically beat when conditions align; the large variance suggests analyst models lack visibility rather than fundamental deterioration.
Natera has received positive news sentiment at a score of +0.67 and is exhibiting a breakout chart pattern with golden cross, above all moving averages, and RSI at 60, suggesting institutional accumulation is supporting the bullish fundamental thesis.
→StableBull case
- Expectation
- Price reaches the analyst consensus target of $234.05 within 12 months, representing approximately 7.9% upside from current levels.
CounterThe asymmetry ratio of only 0.6 means downside risk of 13.1% outweighs the 7.9% upside, and three consecutive earnings misses suggest the market has already discounted some of the good news.
Per-dimension breakdown
Quality
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 9.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.9 |
| FCF quality | 4.1 |
| Moat | 7.2 |
| Rule of 40 | 7.5 |
| Piotroski F | 8.9 |
- ▸FCF-positive despite GAAP loss (FCF margin 5%, FCF yield 0.4%)
- ▸Rule of 40: 44 (pass)
- ▸Strong Piotroski F-Score: 8/9
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 39% YoY
Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 74)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.0 |
| Analyst rating | 7.5 |
| Price target | 4.5 |
- ▸LLM news sentiment: +0.61 (n=5)
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $62,196,566 (0.167% of mkt cap)
Peer rank
2.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.8 |
| quality rank | 1.8 |
| growth rank | 8.5 |
- ▸Industry growth leader
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.4 |
| 52w position | 9.8 |
Risk (lower is worse)
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.7 |
| days to cover | 8.8 |
| volatility | 0.7 |
| put call | 6.7 |
| implied vol | 3.0 |
| max pain risk | 3.0 |
| beta | 4.9 |
| debt equity | 9.5 |
| news risk | 5.0 |
- ▸High IV: 62%
- ▸Above max pain $110
Catalyst
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 9.2 |
| news activity | 8.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.7>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.70
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.9=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.88
Upside
-13.1%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.54>1.3
Investment implication
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.9=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.88 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Sentiment at 6.8, and Momentum at 6.7; the weakest are Value at 1.8, Peer rank at 2.8, and Technical at 3.4. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.88 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Natera is ranked as the industry growth leader in diagnostics and research with revenue growing 39% year-over-year, a perfect growth score of 10.0, and a Rule of 40 score of 44, reflecting a rare combination of high growth and improving profitability.
Trip ifRevenue growth rate falls below 20% year-over-year for 2 consecutive quarters.
- P2Natera has achieved FCF-positive status despite GAAP losses, with a free cash flow margin of 5% and FCF yield of 0.4%, signaling the business has crossed an important inflection point where growth spending is generating sustainable cash returns.
Trip ifFCF margin turns negative for 2 consecutive quarters or free cash flow falls below zero for any single quarter.
- P3Natera has missed analyst EPS estimates in 3 of the last 4 quarters, with the most recent miss of -8.5% indicating that the company's cost structure is growing faster than analysts model even as revenues outperform.
Trip ifEPS surprise falls below -20% in any single quarter or negative surprises occur in at least 3 of the next 4 quarters.
- P4Natera has received positive news sentiment at a score of +0.67 and is exhibiting a breakout chart pattern with golden cross, above all moving averages, and RSI at 60, suggesting institutional accumulation is supporting the bullish fundamental thesis.
Trip ifStock price falls below $195 or news sentiment turns negative below -0.3 for 2 consecutive reporting periods.